Herantis Pharma
1.415
EUR
+0.71 %
4,251 following
HRTIS
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Income statement
Valuation
Quarterly estimates
Income statement
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | |
---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
growth-% | 150.0 % | ||||||||||
EBITDA | -8.5 | -9.7 | -8.1 | 0.2 | -5.0 | -4.1 | -4.8 | -5.3 | -7.7 | ||
EBIT (adj.) | -8.1 | -12.5 | -8.0 | 0.2 | -5.0 | -4.1 | -4.8 | -5.3 | -7.7 | ||
EBIT | -8.1 | -12.5 | -8.0 | 0.2 | -5.0 | -4.1 | -4.8 | -5.3 | -7.7 | ||
Profit before taxes | -8.6 | -12.8 | -9.3 | 0.3 | -5.0 | -4.6 | -4.8 | -5.3 | -7.7 | ||
Net income | -8.6 | -12.8 | -9.3 | 0.3 | -5.0 | -4.6 | -4.8 | -5.3 | -7.7 | ||
EPS (adj.) | -0.88 | -1.15 | -0.55 | 0.01 | -0.25 | -0.19 | -0.20 | -0.22 | -0.32 | ||
growth-% | -1,895.3 % | ||||||||||
Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dividend ratio |
Profitability and return on capital
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | 2027e | 2028e | |
---|---|---|---|---|---|---|---|---|---|---|---|
EBITDA-% | -213,375.0 % | -243,525.0 % | -201,825.0 % | 3,850.0 % | -50,270.0 % | -40,739.4 % | -48,367.6 % | -53,074.7 % | -76,593.7 % | ||
EBIT-% (adj.) | -201,775.0 % | -311,525.0 % | -199,825.0 % | 3,850.0 % | -50,270.0 % | -40,739.4 % | -48,367.6 % | -53,074.7 % | -76,593.7 % | ||
EBIT-% | -201,775.0 % | -311,525.0 % | -199,825.0 % | 3,850.0 % | -50,270.0 % | -40,739.4 % | -48,367.6 % | -53,074.7 % | -76,593.7 % | ||
ROE | -226.6 % | -396.1 % | 1,541.2 % | 12.0 % | -226.5 % | 5,719.6 % | 211.6 % | 72.1 % | 55.3 % | ||
ROI | -109.1 % | -119.5 % | -151.8 % | 3.3 % | -222.0 % | -327.6 % | -322.5 % | -2,123.0 % | -3,063.8 % |